FDA Allows Change to PFO-Migraine Study: End point of MIST II will be migraine reduction rather than complete resolution.

The Food and Drug Administration changed the clinical end point of a large study designed to assess the effectiveness of a patent foramen ovale closure device in patients with migraines.